Zydus Lifesci.

ZYDUSLIFE18 May 2024
Pharmaceuticals
+52.55 (+5.00%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Zydus Lifesci.
Zydus Lifesci.
Pharmaceuticals
ZYDUSLIFE18 May 2024
+52.55 (+5.00%)
1D
1M
6M
1Y
5Y
All

Zydus Lifesci. - Share Price & Details

Lowest Today
1103.95
Highest Today
1103.95
Today’s Open
1103.95
Prev. Close
1051.4
52 Week High
1103.95
52 Week Low
484.95
Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
117.29%
Upper Circuit
Lower Circuit
P/E TTM
41.35
P/B Ratio
7.61
Traded Value(Cr)
0.00
EPS TTM
26.71
Book value
Dividend
0.27%

Price Performance

11.23 %
1 Wk
17.82 %
1 M
21.64 %
3 M
117.29 %
1 Y
57.90 %
YTD

Traded Volume Movement

Technical Details

Support 3
1104
Support 2
1104
Support 1
1104
Pivot Point :
1104
Resistance 1
1104
Resistance 2
1104
Resistance 3
1104

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Zydus Lifesciences Ltd
₹1,103.95(+52.55/5.00%)
1,103.95+52.55111,083.20117.2941.357.61
Lupin Ltd
₹1,660.30(+8.55/0.52%)
1,660.30+8.5575,668.19113.0532.523.67
Ipca Laboratories Ltd
₹1,309.75(+8.05/0.62%)
1,309.75+8.0533,228.9193.9960.415.36
J B Chemicals & Pharmaceuticals Ltd
₹1,843.00(+18.00/0.99%)
1,843.00+18.0028,602.4083.6856.4310.65
Sanofi India Ltd
₹8,869.25(+17.30/0.20%)
8,869.25+17.3020,425.8838.6935.8220.02
376.25+2.252,208.79-12.9516.341.37

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 111133.51 crores. It has reported a sales of Rs. 3172.6 crores and a net profit of Rs. 1405.2 crores for the quarter ended December 2018. The company management includes Pankaj R Patel, Pankaj R Patel,Sharvil P Patel,Mukesh M Patel,Nitin Raojibhai Desai,Dharmishta N Rawal,Apurva S Diwanji,Ganesh N Nayak,Bhadresh K Shah,Dhaval N Soni,Akhil A. Monappa,Upasana Konidela. (Zydus Lifesciences Ltd) among others.
Chairman
Pankaj R Patel
Registered office
Zydus Corporate Park S No 536,Khoraj Sarkhej-Gandhinagar H/W,Ahmedabad,Gujarat,382481
FAX :91-079-26868337/26862365/26862366
Background
Incorporation Year1995
Face Value₹1
Market Lot1

Latest News

Trade setup for Tuesday: 15 things to know before opening bell
Before market opens on Tue, check these things:
📌Key Levels For The Nifty 50
📌Key Levels For The Bank Nifty
📌Nifty Call Options Data
📌Nifty Put Options Data
📌Bank Nifty Call Options Data
📌Bank Nifty Put Options Data
📌Put-Call Ratio
📌India VIX
📌Long Unwinding (31 Stocks)
📌 Short Build-up (30 Stocks)
📌Short-Covering (57 Stocks)
📌 High Delivery Trades
📌Stocks Under F&O Ban
20 May 2024 | 07:29 PM
Trade setup for Tuesday: 15 things to know before opening bell
Before market opens on Tue, check these things:
📌Key Levels For The Nifty 50
📌Key Levels For The Bank Nifty
📌Nifty Call Options Data
📌Nifty Put Options Data
📌Bank Nifty Call Options Data
📌Bank Nifty Put Options Data
📌Put-Call Ratio
📌India VIX
📌Long Unwinding (31 Stocks)
📌 Short Build-up (30 Stocks)
📌Short-Covering (57 Stocks)
📌High Delivery Trades
📌Stocks Under F&O Ban.
20 May 2024 | 07:29 PM
IRIS Business S Consolidated March 2024 Net Sales at Rs 30.35 crore
Reported Consolidated quarterly numbers for IRIS Business Services are:Net Sales at Rs 30.35 crore in March 2024 up 47.66% from Rs. 20.56 crore in March 2023.Quarterly Net Profit at Rs. 4.71 crore in March 2024 up 197.45% from Rs. 1.58 crore in March 2023.EBITDA stands at Rs. 6.66 crore in March 2024 up 96.46% from Rs. 3.39 crore in March 2023.
20 May 2024 | 11:55 PM
JB Pharma aims 12-14% revenue growth over next 2 years: CEO
JB Pharma, majority-owned by investment firm KKR & Co., aims to grow its revenue by 12-14% in the next couple of years with a thrust on domestic and contract development and manufacturing organization (CDMO) businesses, its chief executive Nikhil Chopra said. The company is also foraying into new geographies like Europe and Brazil through tie-ups and product launches.
20 May 2024 | 08:17 PM
Hindustan Aeronautics Consolidated March 2024 Net Sales at Rs 14,768.75 cr
Reported Consolidated quarterly numbers for Hindustan Aeronautics are: Net Sales at Rs 14,768.75 crore in March 2024 up 18.2% from Rs. 12,494.67 crore in March 2023.Quarterly Net Profit at Rs. 4,308.71 crore in March 2024 up 52.19% from Rs. 2,831.18 crore in March 2023. EBITDA stands at Rs. 6,458.57 crore in March 2024 up 62.77% from Rs. 3,968.02 crore in March 2023.
20 May 2024 | 08:02 PM

How to buy Zydus Lifesci. shares on nse?

To buy Zydus Lifesci. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Zydus Lifesci. share price today?

The Zydus Lifesci. shares price on nse is Rs.1103.95 today.

What is the market cap of Zydus Lifesci. shares on NSE ?

The company has a market capitalization of Rs.111083.20Cr

What is the PE & PB ratio of Zydus Lifesci. shares ?

PE is 41.35 and PB is 7.61

What is the 52 Week High and Low of Zydus Lifesci. shares?

Zydus Lifesci. stock price high: Rs.1103.95 Zydus Lifesci. stock price low: Rs.484.95

What is Zydus Lifesciences' stock forecast?

With a new 52-week high, the Zydus Lifesciences stock is expected to outperform in the near term. The average target as of May 11, 2023, is Rs. 521 – a 1.41% increase from the current price of Rs. 513.75.

What is Zydus Lifesciences stock's highest price ever?

The highest price ever for Zydus Lifesciences was Rs. 650.50 on 4th June 2021. 

What is the Zydus Lifesciences stock price target for 2024?

Zydus Lifesciences continues to build a robust product pipeline in innovative, branded generics, as well as genetics categories. Further, the operational efficiency is expected to drive better-than-industry growth in the DF segment. However, analysts at Motilal Oswal have reiterated a ‘neutral’ outlook on the stock, given limited upside from the current levels.

Does Zydus Lifesciences have a solid foundation?

Zydus Lifesciences has a solid foundation that has triggered its recent bullish run. It has a strong presence in the pharmaceutical industry and has been operating for several decades in the development, manufacturing, and marketing of a wide range of healthcare products, including pharmaceuticals, diagnostics, herbal products, and wellness products. With a recent FDA clearance on a pulmonary drug and better-than-expected Q3 profits, Zydus has shown stable and reliable growth. 

What is the Zydus Lifesciences stock dividend payout date?

Zydus Lifesciences is expected to pay its stock dividend in July. The company consistently paid dividends in July for the past two years.

What is the most recent Zydus Lifesciences stock news?

Zydus received the USFDA nod to manufacture and market drugs for osteoporosis, ulcer, blood pressure, heart disease, and pulmonary infections, and general anti-inflammatories. Furthermore, it is looking to sell its clinical research business for close to USD 200 million.